Definium Therapeutics (NASDAQ:DFTX) Trading Up 5.3% on Analyst Upgrade

Definium Therapeutics, Inc. (NASDAQ:DFTX) shot up 5.3% on Tuesday after Robert W. Baird raised their price target on the stock from $37.00 to $57.00. Robert W. Baird currently has an outperform rating on the stock. Definium Therapeutics traded as high as $39.13 and last traded at $38.63. 2,758,190 shares traded hands during mid-day trading, an increase of 35% from the average daily volume of 2,041,882 shares. The stock had previously closed at $36.67.

A number of other analysts also recently issued reports on DFTX. Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the company an “outperform” rating in a report on Monday. Canaccord Genuity Group set a $60.00 price objective on shares of Definium Therapeutics in a report on Monday. HC Wainwright raised their price objective on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Wolfe Research initiated coverage on Definium Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 target price on the stock. Finally, Stifel Nicolaus set a $30.00 price target on Definium Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 16th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $46.08.

Trending Headlines about Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported positive Phase 3 Emerge results for DT120 in major depressive disorder, with the study meeting the primary endpoint and all key secondary efficacy endpoints, reinforcing the drug’s commercial potential. Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
• Positive Sentiment: Robert W. Baird raised its price target on DFTX and maintained an outperform rating, signaling higher analyst confidence in the stock’s upside after the trial data. Definium Therapeutics had its price target raised by Robert W. Baird
• Positive Sentiment: Needham also lifted its price target and reiterated a buy rating, adding to the bullish analyst response following the clinical readout. Definium Therapeutics had its price target raised by Needham & Company LLC
• Neutral Sentiment: Definium said it will host a webcast to discuss the Phase 3 results, which should provide more detail on the data but is not itself a new catalyst. Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
• Negative Sentiment: The company also announced a proposed $500 million public offering, which could dilute existing shareholders and may temper some of the enthusiasm around the strong trial results. Definium Therapeutics, Inc. Announces Proposed Public Offering

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Cerity Partners LLC increased its holdings in Definium Therapeutics by 2.4% during the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock worth $322,000 after purchasing an additional 1,165 shares during the period. Creative Planning grew its holdings in Definium Therapeutics by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after acquiring an additional 1,655 shares in the last quarter. Rathbones Group PLC increased its position in Definium Therapeutics by 7.1% during the 3rd quarter. Rathbones Group PLC now owns 30,200 shares of the company’s stock valued at $356,000 after purchasing an additional 2,000 shares during the period. Bay Rivers Group increased its holdings in Definium Therapeutics by 14.3% during the fourth quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock valued at $214,000 after buying an additional 2,000 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares during the period. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The firm has a market capitalization of $3.85 billion, a P/E ratio of -15.51 and a beta of 2.37. The stock’s fifty day simple moving average is $22.98 and its 200 day simple moving average is $18.58.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). On average, equities research analysts predict that Definium Therapeutics, Inc. will post -2.3 EPS for the current year.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.